RG002 / RinuaGene Biotech - LARVOL DELTA

An Open, Phase I/II Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RG002 Injection, an mRNA Product, in Subjects with Human Papillomavirus (HPV) 16 and/or HPV18-Associated Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN23) (ChiCTR) - P1/2 | N=24 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Renjing (Suzhou) Biotechnology Co., Ltd

New P1/2 trial • Gynecology • Oncology

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (clinicaltrials.gov) - P1/2 | N=39 | Not yet recruiting | Sponsor: RinuaGene Biotechnology Co., Ltd.

New P1/2 trial • Cervical Cancer • Gynecology • Infectious Disease • Oncology